Ten analogues derived from oxytocin, deamino-oxyt ocln and deamlno-carba-oxytocln were prepared, which contained a n-amino acid in the position 2 of the parent system. The following n-amino acids were introduced: tyrosine, phenylalanine, p-mcthylphcnylalanine, p-ethylphenylalanine and Ocethyltyrosine. Combination of two structural features which alone lead to strong inhibitors (a suitable c-amino acid in position 2 and a penicillamine moiety in position I) did not enhance the inhibitory effect. Compounds containing a-tyrosine are weak agonists in the uterotonic assay; in case of Lcarba-analogues they can be converted into sulfoxides with low inhibitory activity. Analogues with n-phenylalanine substituted in the para-position arc the most potent antagonists of the uterotonic effect of oxytocin (pAz = 8'73) in vitro.
Recently, there is a considerable interest in the preparation and study of neurohypophyseal hormone analogues with inhibitory activity towards oxytocin and vasopressin in a great variely of biological tests' -3. These compounds are interesting not only because of their possible use in the study of mechanism of action or spatial arrangement but they may also find use in the clinical therapeutical practice. There are several structural modifications leading to oxytocin analogues with inhibitory effectsin the uterotonic test. We may mention the alkylation of the tyrosine" hydroxyl'-7, particularly with simultaneous acylation of the primary o-amino group of cysteine in position 1 (ref. 8 -11 ) or its replacement by a hydrogen atom!", Particularly important is the attachment of two methyl groups'3.'4, two ethyl groups" or a cyclopentamethylene group'6 to the~-carbon atom of cysteine in position 1 which might be combined with deamination in this position. Various combinations of this modification with substitution of the amino acids have been realized 2 ,3, '4,' 7 -24 (in positions 2, 4, 7 and 8) which gave very strong inhibitors. In the oxytocin series, replacement of tyrosine in position 2 by its n-enantiomer leads to analogues of very low biological activity",2., Introduction of an-amino acid other than tyrosine (such as phenylalanine-Z, pentafiuorophenylalanine-Iv", 3-nitrotyrosine 29 , leucine'· or tryptophan") gives analogues with a certain inhibitory activity. Interestingly, the compound containingO-ethyl-D-tyrosine showed" an intrinsic activity in the in vitro uterotonic test which was .even higher than that of the analogue with the t-enantiomer 7 (which, contrariwise, in certain experimental arrangement had an inhibitory effect). A similar modification (introduction ofO-alkylon-tyrosine) of [1-(p-mercapto-p,p-cyc1opentamethylenepropionic acid), 4-valine, 8 -arginine]vasopressin gave analogues with inhibitory activity in. the antidiuretic as well as pressor tests; however, also the corresponding analogues with the L-amino acid in position 2 showed inhibitory activity, similarly to the compound with unsubstituted n-tyrosine 32 ,33 . If, however, n-tyrosineis introduced into the vasopressin molecule as the only structural change, the resulting analogue ([2-D-tyrosine, 8 -arginine]vasopressin) exhibits relatively high vasopressin-like activities'". This corresponds to the assumptions about the spatial arrangement of the tyrosine side chain in the vasopressin molecule 2 .,'4. n-phenylalanine or an aliphatic n-amino acid in position 2 showed inhibitory activity in the antidiuretic, pressor and uterotonic tests, the ratio of the inhibition constants in various assays depending on the type of the aliphatic amino acid in position 2 (rer.'3) or in position 4 (ref. '·) .
A combination of deamino-penicillamine in position I with an alky!tyrosine in position 2 increases the inhibitory activity in the uterotonic test as compared with [Iedeamino-penicillamlne'[oxytocirr'". The same has been found" also with the corresponding amino derivatives: both [I-penicillamine, 2-0-methyltyrosine]oxytocin and [I-penicillamine, 2-0-methyltyrosine, 8-lysine] vasopressin are strong inhibitors in the nterotonic and pressor tests, On the other hand, acetylation of the a-amino group of penicillamine in position I reduced the inhibitory activity", regardless whether the molecule contained a tyrosine or O-methyltyrosine in the position 2 or not. Interestingly enough, the inhibitory activity increased upen introduction of leucine into the position 2 (ref. 14 ) . The spatial arrangement of the obtained analogue was intensively studied by physical methods and its enhanced inhibitory activity was explained" by a reduction of the sterie strain in the side chains of the amino acids in positions I and 2. The sterie bulk of the substituent in position 2 can be influenced by change in configuration of this amino acid. The tyrosine side chain can form hydrogen bonds and its hydroxyl is assumed'" to be a part of the so-called active site of the oxytocin molecule. On the other hand, hydrophobic interactions of the side chains of amino acids in positions 3, 4, 7 and 8 are very important for binding to the receptor". A change in configuration of the amino acid in position 2 combined with replacement of the hydrophilic hydroxyl by a hydrophobic snbstitnent could strengthen the bond to the receptor with simnltaneons reduction or complete elimination of the intrinsic activity, i.e, the resulting analogne shonld be an inhibitor.
We prepared deamino-6-carba-oxytocin analognes containing D-tyrosine, n-phenylalanine, p-methyl-n-phenylalanine, p-ethyl-D-phenylalanine and O-ethyl-D-tyrosine in the position 2. Deamino-6-carba-oxytocinwas chosenbecause its high uterotonic activity indicates a high affinity towards the uterotonic receptor and its possible oxidation has a snbstantially smaller effect on the biological activities than oxidation of the l-carba-aualogue'Pr'". To checkthe suitability of the6-carbasubstitution combined with deamination for obtaining more potent inhibitors we synthesized oxytocin and deamino-oxytocln analogues with p-ethyl-n-phenylalanine in tbe position 2. We prepared also analogues with penicillamine in position 1 and p-ethylphenylalanine of D or L configuration in position 2.
The analognes were prepared by stepwise synthesis of the chain nsing active esters. Acylations with phenylalanine derivatives (protected with o-nitrobenzenesulfenyl group) were performed with the 2,4,5-trichlorophenyl ester or N-hydroxybenzotriazolyl ester prepared ill situ'", Benzyloxycarbonyl-S-benzylpenicillamine was attached as the p-nitrophenyl ester!", p-Ethyl-DL-phenylalanine was resolved via its phenylacetyl derivative using penicillin amidohydrolase (E.C.3.5.1.11) (ref. 4 2 ." ) . n-Tyrosine was alkylated with diethyl snlfate as o-nitrobenzenesulfenyl derivative in which the acylation of the amino gronp as well as the alkylation at the oxygen conld be curried out withont isolation of the N-acyl intermediate. This alkylation reqnired a substantially higher pH of the reaction mixture and a longer reaction time than the analogous alkylation with dimethyl sulfate and was followed by liquid chromatography.
The carba-analognes were cyclized via N-hydroxybenzotriazolyl ester prepared from hydrochloride of the free octapeptide'". Disulfide-containing analognes were obtained by removal of the protecting gronps with sodium in liquid ammonia and oxidation with potassium ferricyanide. The prodncts were desalted either on Amberlite IRC-50 or using Sep-Pak CiS cartridges'", All the obtained analognes were purified by reversed phase liqnid chromatography.
In syntheses of some analogues we made use of the fact that diastereoisomeric peptides can be easily separated by reversed phase chromatography'vr'". We therefore performed the synthesis with racemic para-substituted phenylalanine derivatives and the formed diastereoisomers were separated only after cyelisation. Their identity was determined by incubation of the hydrolysate with L-amino acid oxidase.
In the diastereoisomeric analognes Ie and If, hydrolysis of the peptide bond D-Phe(Et)-Ile is markedly slower than the L-Phe(Et)-Ile bond, as seen from Table 1 .
Whereas in ali the studied cases the analogue with an aromatic D-amino acid is eluted in the reversed phase chromatography later than the corresponding t-diastereoisomer, the compound containing n-tyrosine differs from its t-analogue only very little (IX = 1'05) and is eluted first. It was particularly important to exclude Collection Czec.!l0slovak Chern, commun. Ivol. 501 [1985J contamination of the analogue Ib with the t-tyrosine analogue (which is very active) and it was therefore purified via its sulfoxide (preparedhy periodate oxidatlon't'') whose capacity factor differs substantially from that of the sulfoxide of the t-tyrosine compound (a = 1'47). The sulfoxide was then reduced with hydrogen bromide in acetone'" ,48 and the obtained analogue purified hy liquid chromatography.
The biological activities of the synthesized analogues are given in Table II . A comparison with uterotonic activities of analogues containing t-amino acids in position 2 can be found in our preliminary communication'P. As seen, both in the in vitro and in vivo assays on uterus the highest inhibitory activity was found with the analogue If containing p-ethyl-n-phenylalanine and carba-substitution in the disulfide bridge. Compounds with non-modified bridge show a slightly lower inhibitory activity, confirming the assumption of higher affinity of carba-compounds towards the uterotonic receptor. The amino compound is. slightly more potent inbibitor than the analogue Ij.<A similar situation was observed also with other analogues containing penicillamine or deaminopeniciliamine 22 • The combination of substitution at the Jl-carbon atom of cysteine in position 1 with introduction of a n-amino acid into position 2 is not of additive character; on the contrary, it reduces slightly the inhibitory activity of the analogue. A comparison of properties of compounds Ii, 1/, and 11 shows that a configurational inversion at the ex-carbon of the amino acid in position 2 alone is more important than the introduction of penicillamine into the position I. However, a mere configurational inversion is not sufficient; very important is removal of hydroxyl from the tyrosine moiety because compounds containing n-tyrosine have their own activity. Alkylation of n-tyrosine preserves a polar oxygen atom in the molecule which, as it seems, is unfavourable for the inhibitory activity. The activity of [2-0-ethyl-o-tyrosine]oxytocin 31 (as compared with the inhibitory activity of compound 1II) again shows the suitability of the carba-modification for obtaining an inhibitor. Amino Acids and Pep tides
Oxidation of carba-analogues of neurohypophyseal hormones affords sulfoxides exhibiting mostly lower activities than the corresponding sulfides'9,.0 (for exceptions see ref!0,.9), the l-carba-analogues being substantially less active than the 6-carba--analogues, We prepared the sulfoxide of compound If which showed about six times lower inhibitory activity than the starting sulfide.
The inhibitory activities found in the in vivo test on the rat uterus parallel the activities determined in vitro. The galactogogic activity was inhibited only in the case of compound If and, surprisingly, its sulfoxide Ig was even more potent inhibitor. On the contrary, compound Ij which does not contain a carba-bridge, shows no inhibition. Except compound I k, the prepared analogues are not effective inhibitors of vasopressin pressor activity. This indicates that for this inhibitor type (contrary to the uterotonic inhibitor) alkylation of the p-carbon atom of cysteine in position 1 represents a much more effective structural feature than configurational inversion in position 2 (compound Ib retains to a high degree its own pressor activity). Except compound Ii, all the prepared analogues exhibit a very low antidiuretic activity.
EXPEillMENTAL
The analytical samples were dried ill vacuo (150 Pa) over phosphorus pentcxide at room temperature. Melting points were determined on a Kofler block and are uncorrected. Thin-layer chromatography was carried out on silica gel plates (Silufol, Kavalier, Czec~oslovakia) in the systems 2-butanol-98% formic acid-water (75: 13·5: 11,5) (SI), 2-butanol-25% aqueous ammonia-water (85: 7·5: 7·5)-{S2). l-butanol-acetic acid-water (4: 1 : 1) (S3). and Icbutanob-pyridine-acetic acid-water (15: 10 : 3 : 6) (S4). Electrophoresis was performed on a Whatman 3MM paper in moist chamber (20V/cm) for 1 h in 1 moll-1 acetic acid (pH 2,4) and a pyridine-acetate buffer (pH 5·7). The compounds were detected by ninhydrin or by the chlorination method. Solvents were evaporated on a rotatory evaporator at bath temperature 30°C; dimethylformamide was evaporated at the same temperature at 150 Pa. Samples for amino acid analyses were hydro- 
) was carried out on an SP~8700 instrument equipped with an SP-8400 detector and an SP-4100 integrator (all from Spectra-Physics, Santa Clara, USA). L-Amino acid oxidase (0' 3 lJlrog) was a Serva product.
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Lebl, Barth, Servttova.Blanlnova.Jost : Dicyclohcxylammonium Salt of o-NitrobenzencsulfenyI-O-ethyl-n-tyrosine c-Nitrobenzenosulfenyl chloride (5-78g) was added to a solution of n-tyroslne (2-83 g) in 4 mol. . 1-1 NaOH (9-8 ml) and dioxane (16 ml), the pH of the mixture being kept at 10 and the temperature below Soc. After stirring for 30 min, diethyl slllfate(6'9 g) and 4 mol I-I NaOH were added so as to keep the pH at 10'7. The alkylation course was followed by reversed-phase HPLC (70% of methanol and 30% of 0'05% aqueous trifluoroacetic acid; kNp5Tyr = 2'21, kNp5Tyr(Et) = 9'56).
After disappearance of the starting compound (80 min), the mixture was filtered, extracted with ether and ethyl acetate and the aqueous layer was acidified at O°C with 0·5 molI-1 H 2S04 to pH 3 and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, concentrated and poured into an ethereal solution of dicyclohexylamine (3'44 ml in 200 ml). After standing overnight the crystals were collected on filter and dried, affording 6·5 g (76%) of the product, m.p. 174-178°C, [lXlo -49" (c 0'19; methanol). For C29H.uN30SS (543,7) calculated: 64'06% C, 7'60%H, 7'73% N; found: 64·53% C, 7·55% H, 7'86% N.
General Method of Preparation of Octapeptides IIb-II!
The dicyclohexylammonium salt of the amino acid derivative (0'8 mmol) was suspended in ethyl acetate (30 ml) atO°C and the amino acid derivative was liberated by addition of 0'05 moll-1 H 2S04 , The ethyl acetate solution was dried over sodium sulfate and taken down. The residue was dissolved in dimcthylformamide (4 ml), Nehydroxybenzotriazole (122 mg) was added, and, after cooling to OaC, dicyclohexylcarbodiimide (182 mg). After stirring for 1 h at DoC and 1 h at room temperature, the mixture was filtered into a flask containing the heptapeptide IIa (350 mg). The solid cake was washed with dimethylformamide (3 ml) and the obtained solution was stirred for 12 h at room temperature. After filtration and evaporation of solvent, the residue was triturated with ether and water, the product was dried and an analytical sample was precipitated with ether from dimethylformamide; its properties are given in Table III .
o~Nitrobenzenesulfenyl-p~ethyl-DL-phenylalanyl-isoleucyl-glutaminyl-asparaginyl -Swbenzylcysteinyl-prolyl~leucyl~glycine Amide (II/b)
A solution of the heptapeptide II/a (2·5 g) in dimethylformamide (100 ml) was mixed with 3·4 moll-1 Hel in ether (1' 7 ml). After standing for 5 min at room temperature, the heptapeptide hydrochloride was precipitated with ether, filtered, dried ill vacuo and dissolved in dimethylformamide (100 ml). o-Nitrobenzenesulfenyl-DL-p~ethylphenylalanine 2,4,5-trichlorophenyl ester (1,8 g) was added, the mixture was adjusted to pI-I 8 (moist indicator paper) and stirred at room temperature for 130 h. The solution was concentrated to a small volume, the product was precipitated with ether, filtered, washed with ether and water and dried ill vacuo; yield 3·1 g (89%) of IIIb (for data see Table ill ).
Benzyloxycarbonyl-S~benzylcysteinylkp·ethyJ-DL-phenylalanylwisoleucylwglutaminylwasparagi nyI-S-benzylcysteinyl~prolyl-Jeucyl-glycine Amide (llIe)
The octapeptide IIIb (0·5 g) was dissolved in dimethylformamide (25 ml -----_.,,-------,--",-- 
,,_._--
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Cys(Bzl).
was mixed with 3'45 mollt HCI in ether. After standing for 5 min the product was precipitated with ether, filtered, dried in vacuo and dissolved in dimethylfcrmamide (23 rot). p-Nitrophenyl ester of benzyloxycarbonyl-S-benzylcysteine (0'8 g) was added, the mixture was adjusted to pH 8 with Nrethylpiperidine, stirred at room temperature for 125 h, and concentrated to a small volume. Theproduct was precipitated with ether, filtered, washed consecutively with ether, 1 mollt act, water, 0·5 mol 1-1 NaHC0 3 • water, and dried; yield 0-42 g (73%). For data see Table III .
Benzyloxyearbonyl-S-benzylpenicillaminyI-p-ethyl-DL;.phenylalanyl-isoleucyl-glutaminyl--asparaginyl-S~benzylcystcinyl-prolyl-Ieucyl-glycineAmide (IIIe).
Bcnzyloxycarbonyl-S-benzylcysteine p-nitrophenyl ester (0'9 g) was added to a solution of the octapeptide hydrochloride prepared in the same manner as in the case of II/c. The condensation and work up were carried out as described for compound I1Ie, yielding 0·46 g of IIIe (Table III) .
A solution of the octapeptide hydrochloride, prepared as described for IIIe, was adjusted to pH 8 with Neethylpiperidine. S-Benzylmercaptopropionic acid (95 mg), followed by N-hydroxybenzotriazole (62 mg), was added and the mixture was cooled to -20
GC and treated with dicyclohexylcarbodiimide (104 mg). After stirring at -20"C for 1 h, at DoC for 30 h, and at room temperature for 2 h, the mixture was filtered and taken down. The residue was suspended in water, filtered, washed successively with. I mol 1-1 Hel, water and ether and dried, affording 380 rng of the product whose properties are given in Table III. [2-o-Phenylalanine]deamino-6-carba-oxytocin (Ie)
A solution of the octapeptide IIe (150 mg) in dimethylformamide (4 ml) was mixed with 3·2 mol . . 1-1 HCI in ether (0,4 ml). After standing for 6 min at room temperature, the octapeptide hydrochloride was precipitated with ether. The hydrochloride was reprecipitated from dimethylformamide with ether, filtered, dried in vacuo and dissolved in dimethylformamide (4 mI).N--Hydroxybenzotriazole (l81 mg) was added, the mixture was cooled to DoC and treated with dicyc1ohexy1carbodiimide (200 rng). After stirring at DoC for 1 h and at room temperature for 1·5 h, the separated crystals of dicyetohexylurea were filtered off and the filtrate was introduced into warm (45°C) methanol (150 ml). The mixture was adjusted to pH 8·5 with N-ethylpipcridinc, kept at 45°C for 2 h and concentrated to a small volume. The product was precipitated with ether, filtered and dried in vacuo; yield 140 mg. A part (30 mg) was dissolved in aqueous methanol
(1 : 1, 10 ml), applied on a column of PartisH ODS~2 (50 X 0·9 cm) and eluted with a mixture of 55% methanol and 0'05% aqueous trifluoroacetic acid. The product-containing fraction (k' = 7'3) was taken down ill llaeuo and freeze-dried, affording 6·5 mg of the product Ic, pure according to HPLC and TLC. Its properties are given in Table IV. [2-0-Tyrosine[deamino-fi-carba-oxytocln (Ib) The octapeptide IIb. (ISO mg) was cycllzed in the same manner as the analogue Ic. The crude product was purified on the same column using a mobile phase containing 40% of methanol. Freeze-drying of the product fractions afforded 22 mg (16%) of the product which, according to HPLC of sulfoxides prepared by periodate oxidation, contained 0'8% of the i.-tyrosinc analogue (compared with the authentic sultoxide-"). Therefore, a part of the product (10 mg) was Tyr-l-Tyrffit), h
Cys, I Cys+ Pen.
.. .
. . e oxidized with periodate and purified again on the above-mentioned column (elution with 35~"m ethanol). A part of the sulfoxide, obtained by freeze-drying of the corresponding fractions, was used for.biological assays, another part (7 rng) was suspended in acetone (200 Ill), treated with 35% HBr in acetic acid (200 Ill) at room temperature for 5 min and again purified on a reversed phase column (40% methanol) to give 4'6 mg of the compound.
[2-p-Methyl-D-phenylalanine]deamino-6-carba_oxytocin (Id) The octapeptide IId (280 rug) was cyclized as described for the analogue Ie. A part of the crude product (lOOmg) was dissolved in a mixture of methanol (4 ml) and water (6 ml) and applied on a column of Partisil ODS (50 X 0'9 em). Elution with a mixture of methanol (55%) and 0'05~ã queous trifluoroacetic acid afforded fractions of k' = 5·7 (12'6 mg) and k' = 7'6 (13'7 mg), the former containing a compound identical with the already described [2-p-methyl-L-phenylalanine]-deamino-ti-carba-oxytocin. The acid hydrolysate of both fractions was incubated with L-arnino acid oxidase which removed p-methylphenylalanine from the former but not from the latter material. Properties of the analogue Id are given in Table IV. [2-p-Ethyl-D-phenylalanine]deamino-6-carba-oxytocin (If) Cyclisation of the octapeptide lIe (300 mg) was carried out as described for the analogue Ie and afforded 249 mg of the crude product. This material was dissolved in a mixture of methanol (to ml) and water (18 ml) and the filtered solution was purified in three portions on a column of Partisil ODS (50 X 0·9 em) using methanol-0'05% trifiuoroacetic acid (56 : 44) as the mobile phase. Concentration and freeze-drying of fractions of k' = 9·4 gave 68 mg of the product whose properties are given in Table IV. [2-p-Ethyl-D-phenylalanine]deamino-6-carba-oxytocin Sulfoxide (/g) Sodium periodate was added to a solution of the analogue 11(4 mg) in aqueous methanol (l : 1; 400 Ill). After standing for 2 h at room temperature, the mixture was applied on a column of Partisil ODS (50 X 0·9 em) and eluted with a methanol-water (3 : 2) mixture. Freeze-drying of the product fractions afforded 2·8 rng (64%) of the product, R F 0'14 (51) The octapeptide III (130 rug) was cyclized in the same way as described for the analogue Ic, affording 135 mg of the crude product. A part of this material (30 mg) was dissolved in a methanol-water mixture (4: 6), applied on a column of Partlsil OD8-2 (50 X 0·9 ern) and eluted with a mixture of methanol and 0'05% trifluoroacetic acid (1 : 1). The fraction of k' = 26'3 was concentrated and freeze-dried, affording 6·2 mg of the product, pure according to HPLC and TLC. Its properties are given in Table IV. [2-p-Ethyl-D-phenylalanine]deamino-oxytocin (If) The peptide IIId (50 mg) was dissolved in liquid ammonia and reduced with a sodium rod until the blue colouration persisted for I min. The excess sodium was destroyed with a drop of acetic acid and the mixture was freeze-dried. The residue was dissolved in 0·1 mol 1- the solution was diluted to 100 ml and adjusted to pI-1 7 with 0:1 moll-1 NaOH; A solution of K 3Fe(CN)6 (25 mg in 5 ml of water) was added during Zu rnin the pl-l value being kept at 7.
After stirring for 40 min at room temperature, the mixture was adjusted to pH 4 by addition of acetic acid and applied on a column of Scpharon SIwC-18 (25 X 0·4 em} by. means of a high pressure pump. The column was washed with water and the peptides were eluted with a mixture of SO% methanol and 0·05% aqueous trifiuoroacetic acid. The eluate was concentrated ill vacuo, freeze-dried, the residue was again dissolved in aqueous methanol (1 :1; SmI) and applied on a column of Partisil ODS (50 X O·gem). Elution with a mixture of methanol and O'05/~aqueous trifiuoroacetic acid (65 : 35) afforded two fractions of k' = 10'2 (8'1 mg: 3S%) and k' = 15'9 (7'6 mg; 36%). The former product contained p-ethyl-L-phenylalaninewhereas the latter contained p-ethyl-c-phcnylalantne (according to incubation of the hydrolysate with r.-amino acid oxidase). The properties of the latter compound are given in Table IV. [2-p-Ethyl-n-phenylalanine[oxytocin (II) The nonapeptide IlIc (200 mg) was. reduced and oxidized as described for the compound I], The cyclization solution was applied on a column of Amberlite IRC-50 (30 ml), the column was washed with 0'25% acetic acid and the peptides were eluted with 50% acetic acid; The product obtained by freeze-drying was dissolved in 50% aqueous methanol (8 ml), applied on a column of Partlsil ODS (50 X 0·9 em) and eluted with a mixture of methanol (60%) with 0·1 moll-1 ammonium acetate (40%), pH 7. Concentration and freeze-drying of the product fraction afforded 16·4 mg (21%) of compound, k' = 11'6. containing p-ethyl-t-phenylalauine, and 15·8 mg (20%) of compound, k' = 23·3, containing p-ethyl-n-phenylalanine (incubation with L-amino acid oxidase). The former product was identical with the sample prepared 16 years ago 7 , stored in the form of lyophilisate at room temperature. For properties of the latter compound see Table IV . As side product we obtained compounds which (according to amino acid analysis) did not contain the terminal tripeptide (k' = 7·3 and 14'4; 5·2 and 3'8 rng, respectively).
[l-Penicillamine, 2-p-ethyl-D-and t-phenylalaninejoxytocln (Lk and Ie)
The nona peptide IIIe (200 mg) was reduced and oxidized as described for the analogue Ii. The cyclization mixture was processed and purified in the same manner as in the case of 11' except that the elution was carried out with a mixture containing 65% of methanol. Concentration and freeze-drying of the corresponding fractions atTorded17·4 mg (22%) of product containing p-ethyl-t-phenylalanine (Ie' = S·05) and 14·6 mg (l9;C;;) of compound containing p-ethyl-n-phenylalanine (k' = 13·S); for their properties see Table IV .
Pharmacological Methods
Uterotonic activity was determined on an isolated strip of rat uterus 51,52. the activity ill vivo was estimated according to PIiska 53. Galactogogic activity was determined on ethanol-anesthetized rats 54 • 55, pressor activity on despinalized rats 56 and antidiuretic y.otency on anesthetized rats 57,58. Inhibitory properties were expressed by the pA., value; for the test in vitro (rat uterus) the recornmendations-" were obeyed, for the assay in vivo;e followed the described method 1 5 , 6 
